Skip to main content
PMC home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1997 Nov;90(11):612–617. doi: 10.1177/014107689709001106

Escherichia coli and ulcerative colitis.

D Burke 1
PMCID: PMC1296671  PMID: 9496273

Full text

PDF
614

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennet J. D., Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989 Jan 21;1(8630):164–164. doi: 10.1016/s0140-6736(89)91183-5. [DOI] [PubMed] [Google Scholar]
  2. Burke D. A., Axon A. T. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ. 1988 Jul 9;297(6641):102–104. doi: 10.1136/bmj.297.6641.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burke D. A., Axon A. T., Clayden S. A., Dixon M. F., Johnston D., Lacey R. W. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 1990 Apr;4(2):123–129. doi: 10.1111/j.1365-2036.1990.tb00456.x. [DOI] [PubMed] [Google Scholar]
  4. Burke D. A., Axon A. T. HeLa cell and buccal epithelial cell adhesion assays for detecting intestinal Escherichia coli with adhesive properties in ulcerative colitis. J Clin Pathol. 1987 Dec;40(12):1402–1404. doi: 10.1136/jcp.40.12.1402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burke D. A., Axon A. T. Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol. 1987 Jul;40(7):782–786. doi: 10.1136/jcp.40.7.782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Burke D. A., Clayden S. A., Axon A. T. Serum bactericidal resistance of faecal Escherichia coli and bactericidal competence of serum from patients with ulcerative colitis. J Clin Pathol. 1990 Apr;43(4):316–319. doi: 10.1136/jcp.43.4.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burke D. A., Clayden S. A., Axon A. T. Sulphasalazine does not select for Escherichia coli with adhesive properties in ulcerative colitis. Lancet. 1988 Oct 22;2(8617):966–966. doi: 10.1016/s0140-6736(88)92636-0. [DOI] [PubMed] [Google Scholar]
  8. Cave D. R., Mitchell D. N., Brooke B. N. Evidence of an agent transmissible from ulcerative colitis tissue. Lancet. 1976 Jun 19;1(7973):1311–1315. doi: 10.1016/s0140-6736(76)92649-0. [DOI] [PubMed] [Google Scholar]
  9. Chapman R. W., Selby W. S., Jewell D. P. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986 Oct;27(10):1210–1212. doi: 10.1136/gut.27.10.1210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cooke E. M., Ewins S. P., Hywel-Jones J., Lennard-Jones J. E. Properties of strains of Escherichia coli carried in different phases of ulcerative colitis. Gut. 1974 Feb;15(2):143–146. doi: 10.1136/gut.15.2.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cooke E. M., Filipe M. I., Dawson I. M. The production of colonic auto-antibodies in rabbits by immunisation with Escherichia coli. J Pathol Bacteriol. 1968 Jul;96(1):125–130. doi: 10.1002/path.1700960113. [DOI] [PubMed] [Google Scholar]
  12. Cooke E. M. Properties of strains of Escherichia coli isolated from the faeces of patients with ulcerative colitis, patients with acute diarrhoea and normal persons. J Pathol Bacteriol. 1968 Jan;95(1):101–113. doi: 10.1002/path.1700950112. [DOI] [PubMed] [Google Scholar]
  13. Davies P. S., Rhodes J., Heatley R. V., Owen E. Metronidazole in the treatment of chronic proctitis: a controlled trial. Gut. 1977 Aug;18(8):680–681. doi: 10.1136/gut.18.8.680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dickinson R. J., Branch W. J., Warren R. E., Neale G. Rectal organ culture as a model for the investigation of bacterial adhesion and invasion. J Clin Pathol. 1984 May;37(5):587–591. doi: 10.1136/jcp.37.5.587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dickinson R. J., Varian S. A., Axon A. T., Cooke E. M. Increased incidence of faecal coliforms with in vitro adhesive and invasive properties in patients with ulcerative colitis. Gut. 1980 Sep;21(9):787–792. doi: 10.1136/gut.21.9.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dickinson R. J., Varian S. A., Axon A. T., Cooke E. M. Increased incidence of faecal coliforms with in vitro adhesive and invasive properties in patients with ulcerative colitis. Gut. 1980 Sep;21(9):787–792. doi: 10.1136/gut.21.9.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Giaffer M. H., Holdsworth C. D., Duerden B. I. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut. 1992 May;33(5):646–650. doi: 10.1136/gut.33.5.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gorbach S. L., Nahas L., Plaut A. G., Weinstein L., Patterson J. F., Levitan R. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy. Gastroenterology. 1968 Apr;54(4):575–587. [PubMed] [Google Scholar]
  19. Hartley M. G., Hudson M. J., Swarbrick E. T., Grace R. H., Gent A. E., Hellier M. D. Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis. Aliment Pharmacol Ther. 1996 Apr;10(2):157–163. doi: 10.1046/j.1365-2036.1996.723115000.x. [DOI] [PubMed] [Google Scholar]
  20. Hunt C. M., Harvey J. A., Youngs E. R., Irwin S. T., Reid T. M. Clinical and pathological variability of infection by enterohaemorrhagic (Vero cytotoxin producing) Escherichia coli. J Clin Pathol. 1989 Aug;42(8):847–852. doi: 10.1136/jcp.42.8.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. KOFFLER D., MINKOWITZ S., ROTHMAN W., GARLOCK J. Immunocytochemical studies in ulcerative colitis and regional ileitis. Am J Pathol. 1962 Dec;41:733–745. [PMC free article] [PubMed] [Google Scholar]
  22. KRAFT S. C., FITCH F. W., KIRSNER J. B. HISTOLOGIC AND IMMUNOHISTOCHEMICAL FEATURES OF THE AUER "COLITIS" IN RABBITS. Am J Pathol. 1963 Dec;43:913–927. [PMC free article] [PubMed] [Google Scholar]
  23. Kemler B. J., Alpert E. Inflammatory bowel disease: study of cell mediated cytotoxicity for isolated human colonic epithelial cells. Gut. 1980 May;21(5):353–359. doi: 10.1136/gut.21.5.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ljungh A., Eriksson M., Eriksson O., Henter J. I., Wadström T. Shiga-like toxin production and connective tissue protein binding of Escherichia coli isolated from a patient with ulcerative colitis. Scand J Infect Dis. 1988;20(4):443–446. doi: 10.3109/00365548809032484. [DOI] [PubMed] [Google Scholar]
  25. Lobo A. J., Burke D. A., Sobala G. M., Axon A. T. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment Pharmacol Ther. 1993 Apr;7(2):155–158. doi: 10.1111/j.1365-2036.1993.tb00084.x. [DOI] [PubMed] [Google Scholar]
  26. McCann M. L., Abrams R. S., Nelson R. P., Jr Recolonization therapy with nonadhesive Escherichia coli for treatment of inflammatory bowel disease. Ann N Y Acad Sci. 1994 Aug 15;730:243–245. doi: 10.1111/j.1749-6632.1994.tb44253.x. [DOI] [PubMed] [Google Scholar]
  27. Mee A. S., McLaughlin J. E., Hodgson H. J., Jewell D. P. Chronic immune colitis in rabbits. Gut. 1979 Jan;20(1):1–5. doi: 10.1136/gut.20.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ohkusa T., Okayasu I., Tokoi S., Ozaki Y. Bacterial invasion into the colonic mucosa in ulcerative colitis. J Gastroenterol Hepatol. 1993 Jan-Feb;8(1):116–118. doi: 10.1111/j.1440-1746.1993.tb01184.x. [DOI] [PubMed] [Google Scholar]
  29. Onderdonk A. B., Bartlett J. G. Bacteriological studies of experimental ulcerative colitis. Am J Clin Nutr. 1979 Jan;32(1):258–265. doi: 10.1093/ajcn/32.1.258. [DOI] [PubMed] [Google Scholar]
  30. Onderdonk A. B., Steeves R. M., Cisneros R. L., Bronson R. T. Adoptive transfer of immune enhancement of experimental ulcerative colitis. Infect Immun. 1984 Oct;46(1):64–67. doi: 10.1128/iai.46.1.64-67.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Perlmann P., Hammarström S., Lagercrantz R., Gustafsson B. E. Antigen from colon of germfree rats and antibodies in human ulcerative colitis. Ann N Y Acad Sci. 1965 Jun 30;124(1):377–394. doi: 10.1111/j.1749-6632.1965.tb18972.x. [DOI] [PubMed] [Google Scholar]
  32. SENECA H., HENDERSON E. Normal intestinal bacteria in ulcerative colitis. Gastroenterology. 1950 May;15(1 1):34–39. [PubMed] [Google Scholar]
  33. Tabaqchali S., O'Donoghue D. P., Bettelheim K. A. Escherichia coli antibodies in patients with inflammatory bowel disease. Gut. 1978 Feb;19(2):108–113. doi: 10.1136/gut.19.2.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Taub R. N., Sachar D., Siltzbach L. E., Janowitz H. Transmission of ileitis and sarcoid granulomas to mice. Trans Assoc Am Physicians. 1974;87:219–224. [PubMed] [Google Scholar]
  35. Van der Waaij D., Cohen B. J., Anver M. R. Mitigation of experimental inflammatory bowel disease in guinea pigs by selective elimination of the aerobic gram-negative intestinal microflora. Gastroenterology. 1974 Sep;67(3):460–472. [PubMed] [Google Scholar]
  36. Watt J., Marcus S. N., Marcus A. J. The comparative prophylactic effects of sulphasalazine, prednisolone and azathioprine in experimental colonic ulceration. J Pharm Pharmacol. 1980 Dec;32(12):873–874. doi: 10.1111/j.2042-7158.1980.tb13100.x. [DOI] [PubMed] [Google Scholar]
  37. West B., Lendrum R., Hill M. J., Walker G. Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease. Gut. 1974 Dec;15(12):960–965. doi: 10.1136/gut.15.12.960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. von Wulffen H., Rüssmann H., Karch H., Meyer T., Bitzan M., Kohrt T. C., Aleksic S. Verocytotoxin-producing Escherichia coli O2:H5 isolated from patients with ulcerative colitis. Lancet. 1989 Jun 24;1(8652):1449–1450. doi: 10.1016/s0140-6736(89)90151-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES